Cardiology

Integrating NAFLD as a diabetes complication to be addressed during routine cycles of care could reduce barriers to a NAFLD pathway in primary care, agreed focus group participants.

Type 2 diabetes patients-and their PCPs-may have trouble moving to basal + mealtime insulin from basal insulin alone. Endocrinologist Brian Levy, MD, offers insights.

The psychiatrist-author of "Coping with COVID-19: The Mental, Medical, and Social Consequences of the Pandemic," talks frankly about the pandemic's long-term impact on American health.

Hospitalization rates for men with hypertensive crisis were higher vs for women, but odds of death during hospitalization decreased for both sexes between 2004-2014.

Following AHA's Life's Simple 7 guidelines can reduce the risk of coronary heart disease despite genetic predisposition, according to new study.

In a new statement, the USPSTF determined current evidence is insufficient to recommend for or against screening for AF in older patients.

Results of a new study that used early clinical surrogate markers of metabolic disease find women at greater risk related to suboptimal sleep.

Coronary heart disease prevalence in the US between 2011 and 2018 saw a statistically insignificant change, from 6.2% to 6.0%, respectively.

Available therapies combined with new approaches that address social determinants of health and other barriers to care can help, suggests new statement.

WATCH: The FDA approval of semaglutide 2.4 mg for adults with obesity was "by far the big event in 2021," said Donna Ryan, MD. More from our look back/look ahead interview, here.

A Mayo Clinic study found certain cardiovascular conditions and risk factors are more strongly associated with cognitive decline in middle-aged women than men.

The ADA's annual update to its comprehensive evidence-based standards includes new guidance on diabetes screening, first-line therapies, and comorbid NAFLD/NASH.

Finerenone, the nonsteroidal mineralocorticoid receptor antagonist, significantly reduced new-onset HF and improved other HF outcomes in the FIGARO-DKD trial.

When is aspirin appropriate in primary ASCVD prevention? Should ezetimibe be added to maximal statin therapy in T2D? This quiz tests your guideline savvy.

In a new retrospective analysis, including smoking history in the 2013 ACC/AHA pooled cohort equations significantly improved ASCVD risk prediction.

New research presented at EuroEcho 2021 may help explain why some patients with long COVID-19 experience persistent dyspnea even 1 year after recovery.

AHA Scientific Sessions 2021 recap, tests of clinical knowledge, expert interviews, and more in this roundup from Patient Care Online.

Get a quick look at 12 of the many FDA-approved drugs in 2021 for conditions commonly seen in primary care.

The Guideline Toplines slide-show feature offers busy primary care physicians at-a-glance summaries of new and updated clinical guidelines across therapeutic areas.

Daily e-cigarette use was associated with more than twice the odds of reporting erectile dysfunction vs never using e-cigarettes, independent of other common ED risk factors.

Women and older adults had the highest increases in blood pressure levels during the pandemic, according to new research.

Find out how effective each of 8 ACC/AHA-recommended non-drug interventions is at reducing BP (in mm Hg) in adults with hypertension and normal BP.

In patients with biopsy-proven NASH, the SPLENDOR study is the first to report a medical modality associated with decreased risk of major adverse events.

Treatment with aspirin of patients with cardiovascular risk factors was consistently associated with a greater than 25% risk of incident HF, another strike against the OTC antithrombotic.

AHA 2021: New research showed MK-0616, an investigative oral PCSK9 inhibitor, was associated with a near 65% decrease in LDL-C.